Surgery Partners' acquisition-driven growth is maturing, with revenue growth decelerating to 2.7% in 2026Q2 from 17.5% in 2024Q4, while gross margin contracted from 27.0% to 22.4% over the same period, indicating rising cost pressures.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 10, 2026 | $0.10+72.6% vs $0.06 | $849M+2.3% vs $830M |
Q2 2026 May 5, 2026 | -$0.03+80.0% vs -$0.15 | $811M+1.7% vs $798M |
Q2 2026 Mar 2, 2026 | $0.12-61.3% vs $0.31 | $885M+2.1% vs $867M |
Q4 2025 Nov 10, 2025 | $0.13-31.6% vs $0.19 | $822M-5.2% vs $867M |
MONSEY, N.Y., Nov. 04, 2026 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Surgery Partners, Inc. (NASDAQ: SGRY) (“SGRY”) to HealthSpan Partners for $23.50 per share in cash.
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
NEW YORK--(BUSINESS WIRE)---- $SGRY #BFA--Surgery Partners, Inc. is being Investigated after the $23.50 per share Merger Deal Announced – Investors are Alerted to Contact BFA Law.
On October 6, 2026, Larry Robbins (Trades, Portfolio) of Glenview Capital Management initiated a new position in Surgery Partners Inc (SGRY), acquiring 7,023,33
Benchmark SGRY against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Surgery Partners, Inc. (SGRY)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $23.20 | $3.03B | -33.73 | 6.24% | -2.63% | -2.59% | — | |
| $99.49 | $1.51B | -666.38 | 16.33% | -0.27% | -0.29% | 1.81% | |
| $19.59 | $366.41M | 9.05 | 2.63% | 12.1% | 16.38% | 13% | |
| $208.85 | $3.26B | 29.08 | 16.94% | 7.24% | 10.35% | 1.18% | |
| $124.31 | $2.32B | 20.79 | 23.21% | 7.39% | 9.81% | — | |
| $7.34 | $1.52B | 52.92 | 46.06% | 0.59% | 12.46% | — |
Surgery Partners, Inc. (SGRY) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Surgery Partners, Inc. (SGRY) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 10, 2026·SEC
Jul 24, 2026·SEC
Jun 5, 2026·SEC
Get notified when SGRY posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Surgery Partners, Inc. (SGRY) stock FAQ — growth, dividends, profitability & financials explained
Surgery Partners, Inc. (SGRY) reported $3.37B in revenue over the trailing twelve months. Revenue was $3.31B in fiscal year 2025. That is 1063% more than the $284.6M of fiscal year 2013.
Surgery Partners, Inc. (SGRY) grew revenue by 4.0% over the trailing twelve months, compared with the twelve months before.
No. Surgery Partners, Inc. (SGRY) reported a net loss of $88.6M over the trailing twelve months.
Surgery Partners, Inc. (SGRY) had a return on equity (ROE) of -2.6% over the trailing twelve months. A negative ROE means the company lost money over the period.
Surgery Partners, Inc. (SGRY) generated $187.6M in free cash flow over the trailing twelve months.
